Journal Article Summary
This article investigates the development of a new formulation called Loratadine Nanostructured Lipid Carriers Ocugel (LORA-NLCs Ocugel) to improve the delivery of Loratadine, an antihistamine used to treat ocular symptoms associated with COVID-19. The significance of this study lies in addressing the common ocular manifestations of COVID-19, such as conjunctivitis and eye irritation, which can affect a large number of patients. The research aims to enhance the solubility and bioavailability of Loratadine, which often suffers from poor absorption due to its low solubility in water.
The researchers employed a systematic approach using a full-factorial design to optimize the formulation of LORA-NLCs. They conducted 24 trials to assess various factors affecting the properties of the lipid carriers, including the type of lipids and surfactants used. Key findings revealed that the optimized LORA-NLCs achieved a high entrapment efficiency of 95.78%, a small particle size of 156.11 nm, and improved trans-corneal penetrability compared to traditional aqueous solutions. In vivo studies indicated that the formulation was safe for ocular use, showing no signs of irritation in rabbits and demonstrating enhanced pharmacokinetic parameters, suggesting better drug retention in the eye.
Despite the promising results, the study has limitations, including the use of animal models, which may not fully replicate human responses. Additionally, the long-term effects and stability of the formulation need further investigation. Patients considering this treatment should discuss it with their healthcare provider to understand its suitability for their specific condition and to ensure it aligns with their overall treatment plan for COVID-19-related symptoms.
Medication Safety Note
This journal article summary is provided for educational purposes only and is not medical advice. Always consult a licensed healthcare professional before starting, stopping, or changing any medication.
Article Cited
- Abdelmonem Rehab, Al-Samadi Inas Essam Ibrahim, El Nashar Rasha M., Jasti Bhaskara R., El-Nabarawi Mohamed A.. Fabrication of nanostructured lipid carriers ocugel for enhancing Loratadine used in treatment of COVID-19 related symptoms: statistical optimization, in-vitro, ex-vivo, and in-vivo studies evaluation. Drug Delivery 2022. DOI: 10.1080/10717544.2022.2115164. PMID: 36065090. PMCID: PMC9448409.
Featured Pill Pals Product
Loratadine 10 mg --- 300 Count Bottle --- Generic For Claritin --- Major / Rugby
Loratadine 10 mg --- 300 Count Bottle --- Generic For Claritin --- Major Pharma is available through Pill Pals Pharmacy with cash-pay pharmacy pricing and free shipping where available. No prescription required for eligible over-the-counter purchases.
